XRCC3 Thr241Met polymorphism with lung cancer and bladder cancer: A meta-analysis

Cancer Science

Volumn 101, Issue 8, 2010, Pages 1777-1782

  Sun, Haiming ^a   Qiao, Yuandong ^a   Zhang, Xuelong ^a   Xu, Lidan ^a   Jia, Xueyuan ^a   Sun, Donglin ^a   Shen, Chao ^a   Liu, An ^a   Zhao, Yanling ^a   Jin, Yan ^a   Yu, Yang ^a   Bai, Jing ^a   Fu, Songbin ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

XRCC3 PROTEIN;

ARTICLE; BLADDER CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONTROLLED STUDY; DATA EXTRACTION; DNA POLYMORPHISM; ETHNICITY; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; HUMAN; INFORMATION RETRIEVAL; LUNG CANCER; MAJOR CLINICAL STUDY; MEDLINE; METHODOLOGY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PUBLICATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SENSITIVITY ANALYSIS;

DNA-BINDING PROTEINS; HUMANS; LUNG NEOPLASMS; POLYMORPHISM, GENETIC; URINARY BLADDER NEOPLASMS;

EID: 77954839636     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01608.x     Document Type: Article

References (59)

1. Kiyohara C, Yoshimasu K, Shirakawa T, Hopkin JM. Genetic polymorphisms and environmental risk of lung cancer: a review. Rev Environ Health 2004, 19:15-38.
2. Lichtenstein P, Holm NV, Verkasalo PK. Environmental and heritable factors in the causation of cancer-analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000, 343:78-85.
3. Spitz MR, Wei Q, Dong Q, Amos CI, Wu X. Genetic susceptibility to lung cancer: the role of DNA damage and repair. Cancer Epidemiol Biomarkers Prev 2003, 12:689-98.
4. Yokota J, Kohno T. Molecular footprints of human lung cancer progression. Cancer Sci 2004, 95:197-204.
5. Madeb R, Messing EM. Gender, racial and age differences in bladder cancer incidence and mortality. Urol Oncol 2004, 22:86-92.
6. Pelucchi C, Bosetti C, Negri E, Malvezzi M, La Vecchia C. Mechanisms of disease: the epidemiology of bladder cancer. Nat Clin Pract Urol 2006, 3:327-40.
7. El-Zein R, Monroy CM, Etzel CJ. Genetic polymorphisms in DNA repair genes as modulators of Hodgkin disease risk. Cancer 2009, 115:1651-9.
8. Krupa R, Synowiec E, Pawlowska E. Polymorphism of the homologous recombination repair genes RAD51 and XRCC3 in breast cancer. Exp Mol Pathol 2009, 87:32-5.
9. Pierce AJ, Johnson RD, Thompson LH, Jasin M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev 1999, 13:2633-8.
10. Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 1998, 58:604-8.
11. Matullo G, Palli D, Peluso M. XRCC1, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 2001, 22:1437-45.
12. Lau J, Ioannidis JP, Schmid CH. Quantitative synthesis in systematic reviews. Ann Inter Med 1997, 127:820-6.
13. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959, 22:719-48.
14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-88.
15. Munafo MR, Clark TG, Flint J. Assessing publication bias in genetic association studies: evidence from a recent meta-analysis. Psychiatry Res 2004, 129:39-44.
16. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ (Clinical research ed.) 1997, 315:629-34.
17. Butkiewicz D, Rusin M, Enewold L, Shields PG, Chorazy M, Harris CC. Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis 2001, 22:593-7.
18. Covolo L, Placidi D, Gelatti U. Bladder cancer, GSTs, NAT1, NAT2, SULT1A1, XRCC1, XRCC3, XPD genetic polymorphisms and coffee consumption: a case-control study. Eur J Epidemiol 2008, 23:355-62.
19. Stern MC, Conway K, Li Y, Mistry K, Taylor JA. DNA repair gene polymorphisms and probability of p53 mutation in bladder cancer. Mol Carcinog 2006, 45:715-9.
20. Andrew AS, Mason RA, Kelsey KT. DNA repair genotype interacts with arsenic exposure to increase bladder cancer risk. Toxicol Lett 2009, 187:10-4.
21. Ricceri F, Guarrera S, Sacerdote C. ERCC1 haplotypes modify bladder cancer risk: a case-control study. DNA Repair (Amst) 2010, 9:191-200.
22. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002, 11:1513-30.
23. Han S, Zhang HT, Wang Z. DNA repair gene XRCC3 polymorphisms and cancer risk: a meta-analysis of 48 case-control studies. Eur J Hum Genet 2006, 14:1136-44.
24. Manuguerra M, Saletta F, Karagas MR. XRCC3 and XPD/ERCC2 single nucleotide polymorphisms and the risk of cancer: a HuGE review. Am J Epidemiol 2006, 164:297-302.
25. Hung RJ, Christiani DC, Risch A. International Lung Cancer Consortium: pooled analysis of sequence variants in DNA repair and cell cycle pathways. Cancer Epidemiol Biomarkers Prev 2008, 17:3081-9.
26. Hill CE, Affatato AA, Wolfe KJ. Gender differences in genetic damage induced by the tobacco-specific nitrosamine NNK and the influence of the Thr241Met polymorphism in the XRCC3 gene. Environ Mol Mutagen 2005, 46:22-9.
27. de las Penas R, Sanchez-Ronco M, Alberola V. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006, 17:668-75.
28. Medina PP, Ahrendt SA, Pollan M, Fernandez P, Sidransky D, Sanchez-Cespedes M. Screening of homologous recombination gene polymorphisms in lung cancer patients reveals an association of the NBS1-185Gln variant and p53 gene mutations. Cancer Epidemiol Biomarkers Prev 2003, 12:699-704.
29. Ryk C, Kumar R, Sanyal S. Influence of polymorphism in DNA repair and defence genes on p53 mutations in bladder tumours. Cancer Lett 2006, 241:142-9.
30. Narter KF, Ergen A, Agachan B, Gormus U, Timirci O, Isbir T. Bladder cancer and polymorphisms of DNA repair genes (XRCC1, XRCC3, XPD, XPG, APE1, hOGG1). Anticancer Res 2009, 29:1389-93.
31. Shen M, Hung RJ, Brennan P. Polymorphisms of the DNA repair genes XRCC1, XRCC3, XPD, interaction with environmental exposures, and bladder cancer risk in a case-control study in northern Italy. Cancer Epidemiol Biomarkers Prev 2003, 12:1234-40.
32. Matullo G, Guarrera S, Carturan S. DNA repair gene polymorphisms, bulky DNA adducts in white blood cells and bladder cancer in a case-control study. Int J Cancer 2001, 92:562-7.
33. Hao GY, Zhang YY, Zhang WD, Yang MS, Jia Q. Relationship between XRCC3 gene polymorphism and bladder cancer in the Han population. Journal OF Shandong University(Health Sciences) 2008, 46:612-5.
34. David-Beabes GL, Lunn RM, London SJ. No association between the XPD (Lys751G1n) polymorphism or the XRCC3 (Thr241Met) polymorphism and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2001, 10:911-2.
35. Ryk C, Kumar R, Thirumaran RK, Hou SM. Polymorphisms in the DNA repair genes XRCC1, APEX1, XRCC3 and NBS1, and the risk for lung cancer in never- and ever-smokers. Lung cancer 2006, 54:285-92.
36. Wang Y, Liang D, Spitz MR. XRCC3 genetic polymorphism, smoking, and lung carcinoma risk in minority populations. Cancer 2003, 98:1701-6.
37. Burri RJ, Stock RG, Cesaretti JA. Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiat Res 2008, 170:49-59.
38. Economopoulos KP, Sergentanis TN. XRCC3 Thr241Met polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat 2009, [E pub ahead of print]
39. Huang WY, Olshan AF, Schwartz SM. Selected genetic polymorphisms in MGMT, XRCC1, XPD, and XRCC3 and risk of head and neck cancer: a pooled analysis. Cancer Epidemiol Biomarkers Prev 2005, 14:1747-53.
40. Stern MC, Siegmund KD, Conti DV, Corral R, Haile RW. XRCC1, XRCC3, and XPD polymorphisms as modifiers of the effect of smoking and alcohol on colorectal adenoma risk. Cancer Epidemiol Biomarkers Prev 2006, 15:2384-90.
41. Ruano-Ravina A, Perez-Rios M, Barros-Dios JM. Population-based versus hospital-based controls: are they comparable? Gac Sanit 2008, 22:609-13.
42. Matullo G, Dunning AM, Guarrera S. DNA repair polymorphisms and cancer risk in non-smokers in a cohort study. Carcinogenesis 2006, 27:997-1007.
43. Misra RR, Ratnasinghe D, Tangrea JA. Polymorphisms in the DNA repair genes XPD, XRCC1, XRCC3, and APE/ref-1, and the risk of lung cancer among male smokers in Finland. Cancer Lett 2003, 191:171-8.
44. Lopez-Cima MF, Gonzalez-Arriaga P, Garcia-Castro L. Polymorphisms in XPC, XPD, XRCC1, and XRCC3 DNA repair genes and lung cancer risk in a population of northern Spain. BMC cancer 2007, 7:162.
45. Zienolddiny S, Campa D, Lind H. Polymorphisms of DNA repair genes and risk of non-small cell lung cancer. Carcinogenesis 2006, 27:560-7.
46. Improta G, Sgambato A, Bianchino G. Polymorphisms of the DNA repair genes XRCC1 and XRCC3 and risk of lung and colorectal cancer: a case-control study in a Southern Italian population. Anticancer Res 2008, 28:2941-6.
47. Zhang ZL, Zhou CC, Zhang J, Tang L, Su B. [Relationship between polymorphisms of DNA repair gene XRCC3 and susceptibility to lung cancer]. Zhonghua Jie He He Hu Xi Za Zhi 2007, 30:936-40.
48. Popanda O, Schattenberg T, Phong CT. Specific combinations of DNA repair gene variants and increased risk for non-small cell lung cancer. Carcinogenesis 2004, 25:2433-41.
49. Jacobsen NR, Raaschou-Nielsen O, Nexo B. XRCC3 polymorphisms and risk of lung cancer. Cancer Lett 2004, 213:67-72.
50. Xia W, Zhang Y, Su D, Shi F. Association of single nucleotide polymorphisms of DNA repair gene XRCC3-241 with non-small cell lung cancer. Zhejiang Medical Journal 2008, 30:1291-3.
51. Harms C, Salama SA, Sierra-Torres CH, Cajas-Salazar N, Au WW. Polymorphisms in DNA repair genes, chromosome aberrations, and lung cancer. Environ Mol Mutagen 2004, 44:74-82.
52. Figueroa JD, Malats N, Rothman N. Evaluation of genetic variation in the double-strand break repair pathway and bladder cancer risk. Carcinogenesis 2007, 28:1788-93.
53. Stern MC, Umbach DM, Lunn RM, Taylor JA. DNA repair gene XRCC3 codon 241 polymorphism, its interaction with smoking and XRCC1 polymorphisms, and bladder cancer risk. Cancer Epidemiol Biomarkers Prev 2002, 11:939-43.
54. Broberg K, Bjork J, Paulsson K, Hoglund M, Albin M. Constitutional short telomeres are strong genetic susceptibility markers for bladder cancer. Carcinogenesis 2005, 26:1263-71.
55. Matullo G, Guarrera S, Sacerdote C. Polymorphisms/haplotypes in DNA repair genes and smoking: a bladder cancer case-control study. Cancer Epidemiol Biomarkers Prev 2005, 14:2569-78.
56. Sanyal S, Festa F, Sakano S. Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis 2004, 25:729-34.
57. Andrew AS, Karagas MR, Nelson HH. DNA repair polymorphisms modify bladder cancer risk: a multi-factor analytic strategy. Hum Hered 2008, 65:105-18.
58. Gangwar R, Ahirwar D, Mandhani A, Mittal RD. Do DNA repair genes OGG1, XRCC3 and XRCC7 have an impact on susceptibility to bladder cancer in the North Indian population? Mutat Res 2009, 680:56-63.
59. Fontana L, Bosviel R, Delort L. DNA repair gene ERCC2, XPC, XRCC1, XRCC3 polymorphisms and associations with bladder cancer risk in a French cohort. Anticancer Res 2008, 28:1853-6.